Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I studyChristoph Beglinger, Pharis Mohideen, Christelle Darstein et al.|Endocrine|2012Cited by 18
Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I StudyYves Horsmans, Douglas M. Heuman, Ke Hu et al.|The Journal of Clinical Pharmacology|2012Cited by 9